Especially in women’s health, this former regulatory gray area could help patients who have waited too long for FDA-approved solutions.

The company projects initial revenue generation from its Sildenafil Cream formulation in Q4 2025, backed by its 503B compounding strategy. Daré plans to provide updates in Q2 2025 on strategic ...

Developed and evaluated specifically for women, DARE to PLAY™ Sildenafil Cream is a first-of-its-kind female arousal cream, a non-hormonaltopical ...